cagrilintide/semaglutide vs petrelintide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanisms: Amylin receptor · Amylin/calcitonin receptor (dual) · full Obesity pipeline

cagrilintide/semaglutide · CagriSema

Developed by Novo Nordisk

Phase 3 in Obesitypeptide
Reliable signal

NCT05394519 · Phase 3 · completed

This was a large, randomized, quadruple-blind, placebo-controlled trial in 1,200 patients using percentage body weight change, the standard efficacy measure for obesity treatment. CagriSema reduced body weight by 13.7% versus 3.4% on placebo, a 10.4-percentage-point difference (p<0.001), meeting the primary endpoint.

Next expected readout: March 2027 · NCT07011667 (registry estimate)

Reported efficacy

Relative change in body weight (From baseline (week 0) to end of treatment (week 68)); Achievement of greater than or equal to (≥) 5% weight reduction (From baseline (week 0) to end of treatment (week 68)): Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001) (met)

Result source: NCT05394519

petrelintide

Developed by Zealand Pharma and partners

Phase 3 in Obesitypeptide
Partial signal

NCT06662539 · Phase 2 · completed

The study was randomized and double-blind, used matching placebo, and enrolled 493 participants. Its primary clinical endpoint was change in body weight, but the outcome comparison is not yet available because results have not been posted.

Next expected readout: November 2027 · NCT07589686 (registry estimate)

Reported efficacy

Percent change from baseline in body weight to Week 28 (From Baseline (Day 1) to Week 28): Primary endpoint met: statistically significant weight reduction vs placebo at week 28 in all five dose arms; up to 10.7% mean reduction at week 42 vs 1.7% with placebo (ZUPREME-1, 2026-03-05). (met)

Result source: NCT06662539

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointcagrilintide/​semaglutidepetrelintide
Body weight, % change-13.7% vs -3.4%a−10.3 vs placebowk 68NCT05394519
1 other result
  • -18.4% vs -11.9% wk 68 · Phase 3 · primary NCT05813925
—Trial running · NCT07843485
Weight loss of 5% or more—Not posted · NCT05996848—Trial running · NCT07843485
Weight loss of 10% or more—Not posted · NCT05996848—Trial running · NCT07843485
Waist circumference, change (cm)—Not posted · NCT05996848—Trial running · NCT07843485

Body weight, % change

cagrilintide/​semaglutide
-13.7% vs -3.4%a−10.3 vs placebowk 68NCT05394519
1 other result
  • -18.4% vs -11.9% wk 68 · Phase 3 · primary NCT05813925
petrelintide
—Trial running · NCT07843485

Weight loss of 5% or more

cagrilintide/​semaglutide
—Not posted · NCT05996848
petrelintide
—Trial running · NCT07843485

Weight loss of 10% or more

cagrilintide/​semaglutide
—Not posted · NCT05996848
petrelintide
—Trial running · NCT07843485

Waist circumference, change (cm)

cagrilintide/​semaglutide
—Not posted · NCT05996848
petrelintide
—Trial running · NCT07843485
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

petrelintide
Primary endpoint met: statistically significant weight reduction vs placebo at week 28 in all five dose arms; up to 10.7% mean reduction at week 42 vs 1.7% with placebo (ZUPREME-1, 2026-03-05). NCT06662539 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

cagrilintide/semaglutide

Weight -13.7% vs -3.4% placebo @ 68wk
percent change · % of baseline
NCT05394519 · Phase 3 · sponsor-reported, not registry data
show 1 more result
-18.4% vs -11.9% semaglutide alone @ 68wk
NCT05813925 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: cagrilintide/semaglutide's landscape · petrelintide's landscape